Interesting article. I point to the following paragraph.
He says FDA approval is more expensive and time consuming than endorsement from Australia’s Therapeutic Goods Administration, which, while no picnic, helps support European approval.
I think we have all wondered from time to time why this course of action was not followed for the Vitrogro.